[89Zr]trastuzumab continues to be used primarily in European countries and proven a private tracer for recognition of HER2-positive lesions by Family pet (7), as well as for prediction of reaction to T-DM1, a HER2-targeted therapy (15)
[89Zr]trastuzumab continues to be used primarily in European countries and proven a private tracer for recognition of HER2-positive lesions by Family pet (7), as well as for prediction of reaction to T-DM1, a HER2-targeted therapy (15). HER2-positive in comparison to HER2-detrimental sufferers (p=0.003). A cutoff SUVmax of 3.2, dependant on ROC evaluation, demonstrated positive-predictive worth…